HK Stock Market Move | CARSGEN-B (02171) rose over 4%. CT0596 has received IND approval from the National Medical Products Administration for the treatment of R/R MM patients.

CARSGEN-B (02171) rose over 4%, as of the time of this report, up 4.53% to HKD 13.39, with a trading volume of HKD 8.1968 million. In terms of news, CARSGEN-B announced that CT0596, a universal CAR-T cell product targeting BCMA, has received IND approval from the National Medical Products Administration for the treatment of relapsed/refractory multiple myeloma (R/R MM) patients. The results of the IIT study for CT0596 were presented in a poster at the 2026 European Hematology Association (EHA) annual meeting. CT0596 is a universal CAR-T cell therapy targeting BCMA, developed based on the THANK-u Plus platform independently developed by CARsGen Therapeutics. It is currently undergoing IIT evaluation in R/R MM or plasma cell leukemia (PCL). CT0596 has shown preliminary good safety and encouraging efficacy signals. The company also plans to further explore its potential in other plasma cell tumors and autoimmune diseases driven by self-reactive plasma cells.